Benjamin I. Chung

The Stanford Pigmented Lesion and Melanoma Program, part of the Stanford Cancer Center, specializes in providing precision care for individuals diagnosed with cutaneous and metastatic melanoma, as well as those at increased risk based on mole patterns and family history. Their multidisciplinary team offers comprehensive evaluations, coordinated treatment, and ongoing surveillance, ensuring individualized care plans tailored to meet each patient's needs and goals. With locations in Palo Alto and San Jose, the program is recognized for its advanced treatment options, including access to the latest breakthroughs in melanoma therapy and genetic assessment. The Stanford Comprehensive Cancer Network, an NCI-designated comprehensive cancer center, underscores their commitment to excellence in patient care and support services. Generated from the website

Geoffrey Sonn, MD is a board certified urologist who specializes in treating patients with prostate and kidney cancer. He has a particular interest in cancer imaging, MRI-Ultrasound fusion targeted prostate biopsy, prostate cancer focal therapy, and robotic surgery for prostate and kidney cancer. He was the Stanford principal investigator of a major clinical trial using MRI-guided focused ultrasound to treat prostate cancer. The goal of this trial was to treat prostate cancer with fewer side effects than surgery or radiation.Dr. Sonn was born in Washington State and lived there until leaving for college at Georgetown in Washington DC. After graduating magna cum laude at Georgetown he returned to the West Coast for medical school at UCLA.